Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.1% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded down 5.1% on Tuesday . The company traded as low as $6.15 and last traded at $6.25. 11,376,722 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 25,701,658 shares. The stock had previously closed at $6.59.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RXRX. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Trading Down 1.8 %

The business has a 50-day moving average of $7.71 and a 200-day moving average of $7.09. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -4.23 and a beta of 0.86.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. During the same quarter in the prior year, the firm earned ($0.42) earnings per share. The firm’s quarterly revenue was down 57.8% compared to the same quarter last year. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $25,000. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals during the fourth quarter valued at about $26,000. Private Trust Co. NA acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $27,000. GAMMA Investing LLC boosted its stake in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.